ArticleJournal of bone oncology2026
Clinical application of urinary NTx in patients with bone metastases from lung cancer.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: To investigate the clinical value of urinary N-telopeptide (NTx) of type I collagen in diagnosing bone metastasis (BM) from lung cancer and to optimize a multi-indicator combined detection strategy. Methods: The study enrolled patients from a healthy control group, a lung cancer without bone metastases (LC-nonBM) group, and a lung cancer with bone metastases (LC-BM) group. The diagnostic performance of NTx-to-creatinine ratio (NTx/Cr) was evaluated by comparing biochemical indicators, staging characteristics, and receiver operating characteristic (ROC) curve analysis. Results: NTx/Cr showed statistically significant differences across various stages within the LC-nonBM group ( Conclusion: Urinary NTx/Cr is an effective biomarker for diagnosing bone metastasis in lung cancer, and its level is closely associated with tumor stage and metastatic burden. A multi-indicator diagnostic model combining NTx/Cr, ALP, and Ca significantly enhances diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.